{"id":"apg-2575-lisaftoclax","safety":{"commonSideEffects":[{"rate":null,"effect":"Tumor lysis syndrome"},{"rate":null,"effect":"Cytopenias (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lisaftoclax selectively inhibits BCL-2 and BCL-xL proteins, which are overexpressed in many hematologic and solid malignancies and prevent programmed cell death. By blocking these anti-apoptotic factors, the drug restores the intrinsic apoptotic pathway, allowing cancer cells to undergo programmed death. This mechanism is particularly relevant in cancers with high BCL-2 dependence.","oneSentence":"APG-2575 (Lisaftoclax) is a BCL-2 family protein inhibitor that promotes apoptosis by blocking anti-apoptotic proteins in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:56.394Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory acute myeloid leukemia (AML)"},{"name":"Relapsed or refractory B-cell lymphomas"}]},"trialDetails":[{"nctId":"NCT05147467","phase":"PHASE2","title":"Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2021-12-28","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":75},{"nctId":"NCT07459608","phase":"PHASE2","title":"Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2026-03-10","conditions":"Indolent Lymphoma, WM, MZL","enrollment":75},{"nctId":"NCT06182969","phase":"PHASE1, PHASE2","title":"A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2024-08-09","conditions":"SLE","enrollment":40},{"nctId":"NCT07272499","phase":"PHASE2","title":"Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-09-10","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":25},{"nctId":"NCT06389292","phase":"PHASE3","title":"A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2024-06-11","conditions":"Acute Myeloid Leukemia","enrollment":486},{"nctId":"NCT06641414","phase":"PHASE3","title":"Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2025-01-22","conditions":"Higher-risk Myelodysplastic Syndrome","enrollment":490},{"nctId":"NCT04496349","phase":"PHASE2","title":"A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2021-07-12","conditions":"T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma","enrollment":78},{"nctId":"NCT04501120","phase":"PHASE1, PHASE2","title":"Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2020-09-28","conditions":"Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy","enrollment":458},{"nctId":"NCT06104566","phase":"PHASE3","title":"Global Trial in APG2575 for Patients With CLL/SLL","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2023-12-20","conditions":"CLL/SLL","enrollment":400},{"nctId":"NCT07159906","phase":"PHASE1, PHASE2","title":"Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-09-08","conditions":"Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma","enrollment":62},{"nctId":"NCT04260217","phase":"PHASE1","title":"APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia","status":"COMPLETED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2021-05-30","conditions":"Waldenstrom Macroglobulinemia","enrollment":46},{"nctId":"NCT04494503","phase":"PHASE1, PHASE2","title":"Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2020-08-31","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":123},{"nctId":"NCT03913949","phase":"PHASE1","title":"A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2019-06-03","conditions":"Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma","enrollment":74},{"nctId":"NCT04215809","phase":"PHASE1","title":"Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2020-03-02","conditions":"CLL/SLL","enrollment":144},{"nctId":"NCT05701306","phase":"PHASE1","title":"APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2023-02-28","conditions":"Neuroblastoma, Solid Tumor","enrollment":100},{"nctId":"NCT04946864","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer","status":"SUSPENDED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2021-08-13","conditions":"Breast Cancer, Solid Tumor, Adult","enrollment":65},{"nctId":"NCT03537482","phase":"EARLY_PHASE1","title":"APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2018-08-07","conditions":"Hematologic Malignancies","enrollment":90},{"nctId":"NCT06319456","phase":"PHASE3","title":"A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2024-04-07","conditions":"CLL/SLL","enrollment":344},{"nctId":"NCT04964518","phase":"PHASE1, PHASE2","title":"A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)","status":"UNKNOWN","sponsor":"Ascentage Pharma Group Inc.","startDate":"2021-07-30","conditions":"AML, Adult","enrollment":24},{"nctId":"NCT04942067","phase":"PHASE1, PHASE2","title":"APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"Ascentage Pharma Group Inc.","startDate":"2021-12-23","conditions":"Multiple Myeloma, Amyloidosis","enrollment":108},{"nctId":"NCT04674514","phase":"PHASE1, PHASE2","title":"APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"Ascentage Pharma Group Inc.","startDate":"2021-04-13","conditions":"Multiple Myeloma","enrollment":48},{"nctId":"NCT05495035","phase":"PHASE1","title":"Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-09-01","conditions":"Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"APG-2575(Lisaftoclax )","genericName":"APG-2575(Lisaftoclax )","companyName":"Ascentage Pharma Group Inc.","companyId":"ascentage-pharma-group-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"APG-2575 (Lisaftoclax) is a BCL-2 family protein inhibitor that promotes apoptosis by blocking anti-apoptotic proteins in cancer cells. Used for Relapsed or refractory acute myeloid leukemia (AML), Relapsed or refractory B-cell lymphomas.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}